Multicancer early detection (MCED) tests –⁠ an overview of technologies and clinical evidence

Czech version

Authors: T. Büchler ¹; M. Zubaľ ¹; M. Svoboda ²; J. Halámková ²
Authors‘ workplace: Onkologická klinika 2. LF UK a FN Motol a Homolka, Praha ¹; Klinika komplexní onkologické péče LF MU a MOÚ, Brno ²
Published in: Klin Onkol 2026; 39(Supplementum 1): 17-25
Category: Review
doi: https://doi.org/10.48095/ccko2026S17

Overview

Early detection of cancer is one of the key factors influencing patient prognosis and overall cancer-related mortality. However, current population--based screening programs are limited to only a few selected diagnoses, and many highly lethal malignancies still lack an effective option for early detection. Multicancer early detection (MCED) tests represent a new group of blood-based screening methods aimed at identifying the presence of early-stage cancer across multiple primary sites through a single peripheral blood sample. They mainly rely on the analysis of circulating tumor DNA, including its methylation and fragmentation characteristics, or on combinations with protein markers or the detection of circulating tumor cells. These tests offer high specificity and are able to estimate the most likely site of origin of the tumor, which is crucial for guiding subsequent diagnostic workup. At present, the largest body of evidence is available for methylation-based and multiomic platforms. Prospective studies conducted so far in asymptomatic individuals suggest that MCED tests may enable the detection of cancers at clinically relevant stages, with a relatively low false-positive rate and an acceptable burden of follow-up investigations. At the same time, important limitations remain particularly lower sensitivity in the earliest stages of disease, the absence of standardized diagnostic algorithms following a positive result, and the lack of evidence for an effect on cancer-specific mortality and the incidence of advanced-stage disease. MCED tests therefore cannot yet be considered a replacement for established organ-specific screening programs. However, they appear to be a promising complement to current screening strategies, particularly for the detection of cancers for which no established screening exists. Their future clinical role will depend on the results of large prospective and randomized studies demonstrating their true benefit for both the population and healthcare systems. In addition to strong evidence of clinical benefit, widespread implementation into clinical practice will also require standardization of downstream diagnostic pathways and careful health-economic evaluation.

Keywords:

DNA methylation – Circulating tumor DNA – liquid biopsy – early cancer detection

Sources

1. Guerra CE, Sharma PV, Castillo BS. Multi-cancer early detection: the new frontier in cancer early detection. Annu Rev Med 2024; 75 : 67–81. doi: 10.1146/annurev-med-050522-033624.

2. Rubinstein WS, Patriotis C, Dickherber A et al. Cancer screening with multicancer detection tests: a translational science review. CA Cancer J Clin 2024; 74 (4): 368–382. doi: 10.3322/caac.21833.

3. Brito-Rocha T, Constâncio V, Henrique R et al. Shifting the cancer screening paradigm: the rising potential of blood-based multi-cancer early detection tests. Cells 2023; 12 (6): 935. doi: 10.3390/cells12060935.

4. Ebbert JO, Hawk ET, Chambers CV et al. Multi-cancer early detection tests: attributes for clinical implementation. Cancer Biomark 2025; 42 (2): 18758592241297849. doi: 10.1177/18758592241297849.

5. Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med 2018; 16 (1): 166. doi: 10.1186/s12916-018-1157-9.

6. Phallen J, Sausen M, Adleff V et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9 (403): eaan2415. doi: 10.1126/scitranslmed.aan2415.

7. Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 2021; 32 (9): 1167–1177. doi: 10.1016/j.annonc.2021.05.806.

8. Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020; 31 (6): 745–759. doi: 10.1016/j.annonc.2020.02.011.

9. Chen X, Gole J, Gore A et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun 2020; 11 (1): 3475. doi: 10.1038/s41467-020-17316-z.

10. Nguyen VT, Nguyen TH, Doan NN et al. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Elife 2023; 12: e89083. doi: 10.7554/eLife.89083.

11. Tran LS, Nguyen TH, Nguyen LH et al. Comprehensive validation of a cell-free DNA-based assay for multi-cancer detection: a Vietnamese longitudinal prospective cohort study of 9,024 participants. J Clin Oncol 2024; 42 (23 Suppl): 102. doi: 10.1200/JCO.2024.42.23_suppl.102.

12. Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat Med 2025; 31 (8): 2737–2745. doi: 10.1038/s41591-025-03735-2.

13. Luo H, Li P, Wei W et al. High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing: a retrospective cohort study. J Clin Oncol 2024; 42 (16 Suppl): 3043. doi: 10.1200/JCO.2024.42.16_suppl.3043.

14. Bahadur U, Vishwanath D, Hiremath P et al. CancerSpot: a multi-cancer early detection test using targeted methylation sequencing. Cancer Res 2025; 85 (8 Suppl 1): 2343.

15. Hermann BT, Pfeil S, Groenke N et al. DEEPGEN. Genes (Basel) 2021; 12 (4): 507. doi: 10.3390/genes12040507.

16. Mao M, Li S, Ren Q et al. Integrating multi-omics features for blood-based multi-cancer early detection. JCO Glob Oncol 2023; 9 (Suppl 1): 156.

17. Mao M, Li S, Ren Q et al. A blood-based multi-omics test for multicancer early detection: combined retrospective and prospective studies. Cancer Res 2024; 84 (6 Suppl): 1057.

18. Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020; 369 (6499): eabb9601. doi: 10.1126/science.abb9601.

19. Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med 2021; 59 (8): 1353–1361. doi: 10.1515/cclm-2021-0171.

20. Mao M, Luan Y, Zhong G et al. A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence. JCO Glob Oncol 2023; 9 (Suppl 1): 155.

21. Mao M, Shen Y, Xia Y et al. Large-scale clinical validation of a blood-based, multi-cancer, early detection test across different sample types, platforms, and populations. J Clin Oncol 2025; 43 (16 Suppl): 10521.

22. Mao M, Shen SY, Chang YY et al. OncoSeek 2.0: enhanced-sensitivity blood test for multi-cancer early detection. Cancer Epidemiol Biomark Prev 2025; 34 (9 Suppl): C127.

23. Shen Y, Xia Y, Chang Y et al. A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection. NPJ Precis Oncol 2025; 9 (1): 321. doi: 10.1038/s41698-025-01105-2.

24. Akolkar D, Patil D, Crook T et al. Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer. Int J Cancer 2020; 146 (12): 3485–3494. doi: 10.1002/ijc.32815.

25. Gaya A, Crook T, Plowman N et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol 2021; 129 (3): 226–238. doi: 10.1002/cncy.22366.

26. Buchanan AH, Lennon AM, Rego SP et al. Long-term clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test. J Clin Oncol 2023; 41 (16 Suppl): 3037.

27. Buchanan AH, Lennon AM, Choudhry OA et al. Multiyear clinical outcomes of cancers diagnosed following detection by a blood-based multicancer early detection test. Cancer Prev Res (Phila) 2024; 17 (8): 349–353. doi: 10.1158/1940-6207.CAPR-24-0107.

28. Lennon AM, Buchanan AH, Rego SP et al. Outcomes following a false-positive multi-cancer early detection test: results from DETECT-A, the first large, prospective, interventional MCED study. Cancer Prev Res (Phila) 2024; 17 (8): 355–359. doi: 10.1158/1940-6207.CAPR-23-0451.

29. Schrag D, Beer TM, McDonnell CH et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 2023; 402 (10409): 1251–1260. doi: 10.1016/S0140-6736 (23) 01700-2.

30. Nadauld LD, McDonnell CH, Beer TM et al. The PATHFINDER study: assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel) 2021; 13 (14): 3501. doi: 10.3390/cancers13143501.

31. Klein E, Beer T. Assessing implementation of a multi-cancer early detection blood test for population screening in a clinical practice setting: prospective PATHFINDER cohort study. Cancer Prev Res (Phila) 2023; 16 (1 Suppl): IA022.

32. Giridhar KV, Demeure MJ, Kim RH et al. PATHFINDER 2: a prospective study to evaluate safety and performance of a multi-cancer early detection test in a population setting. Cancer Res 2024; 84 (6 Suppl): 4784.

33. Nabavizadeh N, McDonnell C, Kurbegov D et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER II study. Ann Oncol 2025; 36: S1720. doi: 10.1016/j.annonc.2025.09.076.

34. MedTech Dive. Grail’s multi-cancer early detection test misses study goal. [online]. Available from: https: //www.medtechdive.com/news/grails-multi-cancer-early-detection-test-misses-study-goal/812736/.

35. GRAIL. Landmark NHS-Galleri trial demonstrates a substantial reduction in Stage IV cancer diagnoses, increased Stage I and II detection of deadly cancers, and four-fold higher cancer detection rate. [online]. Available from: https: //grail.com/press-releases/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnoses-increased-stage-i-and-ii-detection-of-deadly-cancers-and-four-fold-higher-cancer-detection-rate/.

36. Nguyen LH, Nguyen TH, Le VH et al. Prospective validation study: a non-invasive circulating tumor dna-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med 2025; 23 (1): 90. doi: 10.1186/s12916-025-03929-y.

37. Nguyen H, Tran LS. Clinical validation of a ctDNA--based assay for multi-cancer detection: an interim report from a Vietnamese longitudinal prospective cohort study of 2795 participants. JCO Glob Oncol 2023; 9 (Suppl 1): 135.

38. Tran LS, Nguyen LH, Nguyen HT et al. Analytical and clinical validation of a circulating tumor DNA-based assay for multicancer early detection. J Clin Oncol 2024; 42 (16 Suppl): 10548.

39. Nguyen LH, Tieu BL, Nguyen TT et al. A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study. Future Sci OA 2024; 10 (1): 2395244. doi: 10.1080/20565623.2024.2395244.

40. Ranade A, Bhatt A, Page R et al. Hallmark circulating tumor-associated cell clusters signify 230 times higher one-year cancer risk. Cancer Prev Res (Phila) 2021; 14 (1): 11–16. doi: 10.1158/1940-6207.CAPR-20-0322.

41. Chhatwal J, Xiao J, ElHabr A et al. The potential of multi-cancer early detection screening in reducing cancer incidence and mortality in high-risk groups: a modeling study. J Clin Oncol 2025; 43 (16 Suppl): 10542.

42. Jamshidi A, Liu MC, Klein EA et al. Evaluation of cell--free DNA approaches for multi-cancer early detection. Cancer Cell 2022; 40 (12): 1537–1549. doi: 10.1016/j.ccell.2022.10.022.

43. Guerra CE, Litton JK, Viswanath CE et al. Multicancer early detection tests at a crossroads: commercial availability ahead of definitive evidence. Am Soc Clin Concol Educ Book 2025; 45 (3): e473834. doi: 10.1200/EDBK-25-473834.

44. Kisiel JB, Ebbert JO, Taylor WR et al. Shifting the cancer screening paradigm: developing a multi-biomarker class approach to multi-cancer early detection testing. Life (Basel) 2024; 14 (8): 925. doi: 10.3390/life14080925.

45. Kansal AR, Tafazzoli A, Shaul A et al. Cost-effectiveness of a multicancer early detection test in the US. Am J Manag Care 2024; 30 (12): e352–e358. doi: 10.37765/ajmc.2024.89643.

46. Wade R, Nevitt S, Liu Y et al. Multi-cancer early detection tests for general population screening: a systematic literature review. Health Technol Assess 2024; 29 (2): 1–105. doi: 10.3310/DLMT1294.

47. Kahwati LC, Avenarius M, Brouwer L et al. Multicancer detection tests for screening: a systematic review. Ann Intern Med 2025; 178 (11): 1591–1604. doi: 10.7326/ANNALS-25-01877.

48. Miller SJ, Sly JR, Rolfo C et al. Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside. Health Aff Sch 2024; 2 (5): qxae039. doi: 10.1093/haschl/qxae039.